SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

KOMZIFTI

KURA·Kura Oncology, Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the U.S. since November 2025.
Why 4/10
KOMZIFTI is already FDA-approved and generating commercial revenue, so the defining binary event (the November 2025 PDUFA) has passed. The next notable catalyst is the ASH 2026 annual meeting (December 2026), where ziftomenib combination data will be presented, but this is a medical conference data readout, not a regulatory binary. With no pending PDUFA or pivotal readout in the next ~12 months, the impact score is capped at 4.
Actionable Insight MIXED

KOMZIFTI is already approved and generating growing revenue, so the defining binary event has passed. Watch for ASH 2026 (December 2026) where ziftomenib combination data in newly diagnosed AML will be presented -- strong data could support a major label-expansion opportunity into the frontline setting, while weak data would cap the upside thesis. Also track quarterly sales growth trajectory as the key near-term value driver.

Price Chart

Loading chart...

Executive Summary

KOMZIFTI (ziftomenib) is a first-in-class, once-daily oral menin inhibitor approved by the FDA in November 2025 for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). Developed by Kura Oncology (NASDAQ: KURA) in partnership with Kyowa Kirin, it is the only approved targeted therapy for this specific AML genetic subtype. The drug is in early commercial stages: Q3 2026 net product revenue reached $13.9 million, growing 53% sequentially with 30% more new patient starts. The stock trades at $7.57, well below the mean analyst target of $31.85, reflecting market skepticism about commercial ramp speed. The next catalyst is the ASH 2026 annual meeting (December 2026), where combination data in newly diagnosed AML could support a much larger label expansion opportunity.

How It Works

KOMZIFTI is a once-daily pill that blocks a protein called menin. In a subset of acute myeloid leukemia (AML) patients whose cancer cells have a specific genetic mutation (NPM1), menin acts like a master switch that keeps the cancer growing. By inhibiting menin, KOMZIFTI turns off that switch, stopping leukemia cell proliferation and allowing normal blood cell production to recover.

Trial Status

KOMZIFTI received FDA full approval in November 2025 based on the Phase 2 KOMET-001 trial in relapsed/refractory NPM1-mutated AML. The drug is now commercially available. Ongoing trials are evaluating ziftomenib in combination regimens for newly diagnosed AML (frontline setting), including combinations with venetoclax/azacitidine and with FLT3 inhibitors (quizartinib, gilteritinib). Data from these combination studies will be presented at ASH 2026 in December.

The Two-Sided Case

▲ Bull Case7
KOMZIFTI is the first and only FDA-approved once-daily oral menin inhibitor for NPM1-mutated AML, a first-in-class targeted therapy addressing a clear unmet need.
Commercial traction is accelerating: Q3 2026 net product revenue of $13.9M grew 53% sequentially, with new patient starts up 30% and total prescriptions rising.
Analyst consensus is strongly bullish: 20 buy/strong buy ratings vs 2 hold, with a mean price target of $31.85 (320% upside from the current $7.57).
CEO Troy Wilson purchased ~$2.35M of stock on the open market in August 2026 at $11-12 per share, a significant insider vote of confidence.
Combination data with venetoclax/azacitidine showed 86% CRc in newly diagnosed NPM1-m AML, supporting a potential label expansion into the much larger frontline setting.
The drug was added to NCCN guidelines as a Category 2A recommended treatment, supporting standard-of-care adoption.
Institutional accumulation continued in Q3 2026, with FMR LLC (Fidelity) adding 77%, Jupiter Asset Management doubling its position, and new buyers entering.
▼ Bear Case5
The stock trades at $7.57, far below the mean analyst target of $31.85, suggesting the market is heavily discounting the commercial opportunity or sees significant execution risk.
Multiple senior executives (CMO, COO, CCO, CLO) sold shares in late September 2026 at ~$10.50, well above the current price, which can signal insider caution about near-term prospects.
Several large institutional holders trimmed or exited positions in Q2 2026, including Millennium Management (-55%), Jane Street (-89%), and American Century (-81%), indicating mixed institutional conviction.
The approved indication (relapsed/refractory NPM1-mutated AML) is a niche population, and competition from other menin inhibitors in development could pressure long-term market share.
The company remains unprofitable, reporting a Q3 2026 loss of $0.78 per share, and will need to continue funding commercial infrastructure and clinical trials.

Upcoming Catalysts

  • ASH 2026 Annual Meeting (December 2026): Eight abstracts on ziftomenib, including four oral presentations featuring first combination data with FLT3 inhibitors (quizartinib, gilteritinib) and longer-term Phase 1b data.
  • Q4 2026 earnings (expected February 2027): Commercial sales trajectory and patient start metrics will be key indicators of market adoption.
  • Potential regulatory filing for frontline NPM1-mutated AML indication if combination data are compelling, though timing is uncertain.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Kura Oncology, Inc. PRESS-RELEASE KURA ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 msn.com3 pharmexec.com4 theglobeandmail.com5 manilatimes.net6 ad-hoc-news.de7 msn.com8 curetoday.com9 sec.gov